NEW GMO FLU VACCINE APPROVED BY THE FDA; FDA once again misleads the public.

The U.S. announced it has approved the use of a new flu vaccine, manufactured by using an insect virus expression system and recombinant DNA technology. The vaccine is a trivalent, meaning that it is a combination of three flu strains.  For the 2012 – 2013 season it is formulated to contain each of the following 3 virus strains: A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Wisconsin/1/2010.

The vaccine is called simply . The claims to have tested the product on approximately 2500 people, with a few “minor” side effects, and warns about a possible major side effect, including Guillian Barre syndrome, ().  is usually characterized by rapidly developing motor weakness and the absence of reflexes. The vaccine product information sheet can be obtained from the website accessible here.

Under warnings and precautions it cites the following:

“The 1976 swine vaccine was associated with an increased frequency of . Evidence for a causal relation of with other vaccines is inconclusive; if an excess risk exists, it is probably slightly more than one additional case per 1 million persons vaccinated. If Guillain-Barré Syndrome () has occurred within 6 weeks of receipt of a prior vaccine, the decision to give Flublok should be based on careful consideration of the potential benefits and risks.”

Numerous scientific studies have, however; indeed demonstrated a causal link between vaccines and , including finding a direct causal relationship between different vaccine manufacturers and the onset of after vaccinations.  A more recent Canadian study demonstrated a small but significant risk of in the vaccine population. is one of the vaccine strains contained in . A 2012 study by Wise et al. published in the journal of epidemiology demonstrates a 57% higher immediate causal link of contracting if vaccinated with PH1N1, (a monovalent single strain vaccine), compared to a non vaccinated population.


Geier, M. et al.,Influenza Vaccination and Guillan Barre Syndrome. 2003. Clinical Immunology 107 (2003) 116–121

De Wals P. et al. Risk of Guillain-Barré syndrome following H1N1 vaccination in Quebec. 2012. JAMA. 2012 Jul 11;308(2):175-81. doi: 10.1001/jama.2012.7342.

Wise M. et al. 2012. Guillain-Barre syndrome during the 2009-2010 H1N1 vaccination campaign: population-based surveillance among 45 million Americans. Am J Epidemiol. 2012 Jun 1;175(11):1110-9. doi: 10.1093/aje/kws196. Epub 2012 May 11.

Be Sociable, Share!

    Leave a Reply

    Your email address will not be published. Required fields are marked *